FigureAsia 35 Under 35 · Healthcare
Levana Sani
Age 33 · Pharmacogenomics and precision medicine · Singapore and Jakarta
Founder behind a pharmacogenomics programme spanning real-world outpatient feasibility and a 1,500-patient precision-prescribing initiative.
- Approximate age at 31 December 2025
- 33
- Field
- Healthcare
- Country or region
- Singapore and Jakarta
- FigureAsia U35 Assessment
- 90.0 / 100
Profile
Career and documented record
Levana Sani has spent years addressing an imbalance in precision medicine: drug-response evidence and commercial tests have been shaped disproportionately by populations outside Southeast Asia. In 2025, a real-world outpatient feasibility study examined how pharmacogenomic testing could be introduced into clinical workflows, documenting practical questions around sampling, interpretation and clinician use rather than treating a genetic report as a self-executing intervention.
Her company also advanced PRECISE-CIP, a programme designed around 1,500 patients and the use of genetic information to guide medication choice. The work sits between laboratory testing, software interpretation and the realities of prescribing in Asian health systems. Sani's personal agency is unusually direct: trained as a scientist, she cofounded the company, led its market and evidence strategy, and has sustained a public partnership with Indonesia's health authorities around genomic capacity.
The programme should not be read as proof that every tested patient experienced a better outcome. Public evidence is stronger on feasibility, implementation and cohort building than on randomized clinical benefit. Its importance lies in creating an Asia-specific evidence base and care pathway where none can be assumed from Western datasets.
FigureAsia selection
Why Levana Sani is on the list
FigureAsia selected Sani because she has joined population representation to clinical implementation. The 2025–2026 record moves pharmacogenomics from a scientific argument into outpatient workflow and a sizeable regional programme. Her score rewards access, agency and Asian significance; it remains conservative on impact because clinical outcome and cost-effectiveness evidence is still developing.
Verified work
The 2025–26 record
Principal milestone
1,500-patient precision-prescribing programme
Evidence record
Peer-reviewed 2025 outpatient feasibility study
Scale or implementation
Formal genomic-development collaboration with Indonesia's health ministry
Field context
The work in its field
Within pharmacogenomics and precision medicine, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
90.0out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in pharmacogenomics and precision medicine, assessed at the documented maturity of clinical implementation and cohort development.
Verified impact
13.5 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
8 / 10
The work creates or materially advances a distinctive capability within pharmacogenomics and precision medicine rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
10 / 10
Named authorship and the documented role of Cofounder and Chief Executive Officer establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4.5 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Indonesian scientist and founder building pharmacogenomics infrastructure in Southeast Asia.
Clinical and scientific validity
6.3 / 7
Clinical and scientific validity is calibrated to clinical implementation and cohort development, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
6.3 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
5.4 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.